HDAC抑制剂调控乳腺癌细胞HER-2表达的研究进展  

Advances in the regulation of HER-2 expression in breast cancer cells by HDAC inhibitors

作　　者：冯元莹 邓怡林 史业辉 FENG Yuanying;DENG Yilin;SHI Yehui(Department of Breast Oncology,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Tianjin Key Laboratory of Cancer Prevention and Therapy,Tianjin's Clinical Research Center for Cancer,Key Laboratory of Breast Cancer Prevention and Therapy,Tianjin 300060,China)

机构地区：[1]天津医科大学肿瘤医院乳腺内科,国家肿瘤临床医学研究中心,天津市“肿瘤防治”重点实验室,天津市恶性肿瘤临床医学研究中心,乳腺癌防治教育部重点实验室,天津300060

出　　处：《现代肿瘤医学》2022年第13期2475-2478,共4页Journal of Modern Oncology

基　　金：国家自然科学基金青年项目(编号:82103281);天津医科大学肿瘤医院临床试验基金一般项目(编号:C1708)。

摘　　要：乳腺癌是女性最常见的恶性肿瘤,约15%~20%的患者呈HER-2过表达,该亚型患者易复发转移,预后较差。HER-2过表达不仅与基因扩增有关,还受表观调控的影响。组蛋白去乙酰化酶抑制剂被认为是靶向癌细胞表观基因组的代表性药物,在HER-2阳性乳腺癌中,组蛋白去乙酰化酶抑制剂可通过下调HER-2表达,与靶向HER-2的大分子单抗表现出协同作用。本文我们将重点概述组蛋白去乙酰化酶抑制剂下调HER-2表达的机制以及在乳腺癌治疗中的研究现状。Breast cancer is the most common malignant tumor in women,and about 15%~20%of patients have HER-2 overexpression,which is prone to recurrence and metastasis and has a poor prognosis.HER-2 overexpression is not only related to gene amplification,but also influenced by epigenetic regulation.Histone deacetylase inhibitors are representative drugs for targeting the epigenome of cancer cells,and in HER-2-positive breast cancer,histone deacetylase inhibitors can show synergistic effects with large monoclonal antibodies targeting HER-2 by downregulating HER-2 expression.In this review,we will focus on an overview of the mechanisms by which histone deacetylase inhibitors downregulate HER-2 expression and the current research progress in the treatment of breast cancer.

关 键 词：组蛋白去乙酰化酶 人表皮生长因子受体2 乳腺癌 表观遗传 

分 类 号：R737.9[医药卫生—肿瘤]